XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules
BO28984
Phase 3 small_molecule active
Quick answer
XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules for Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active